Join. William White on InvestorPlace | March 28, 2023. And, with enough luck, someday those nascent businesses might grow to become formidable companies with budding rosters of life-saving drugs. Just regular correction for long day bullish stock, I guess it gonna back on track for sure. Log in to see them here or sign up to get started. This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. The idea is that more recent information is, generally speaking, more accurate and can be a better predictor of the future, which can give investors an advantage in earnings season. Mino-lok has a market value of 1.5B in the US alone. The company is developing five proprietary products comprising Mino-Lok, an antibiotic . Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Copyright 2023 MarketWatch, Inc. All rights reserved. Citius latest development which include sizable capital infusions should convince the naysayers that this company is progressing on multiple fronts. Ran from $1.90 to $4.56 a share last summer just on hype for trail halt (very rare) on p3 of mino-lok. . Historical and current end-of-day data provided by FACTSET. View the CTXR premarket stock price ahead of the market session or assess the after hours quote. 23. Article printed from InvestorPlace Media, https://investorplace.com/2021/03/capital-raises-and-clinical-programs-prove-progress-ctxr-stock/. Prospective CTXR stock investors deserve a much more in-depth discussion of this fascinating company. ET). The technique has proven to be very useful for finding positive surprises. Cryptocurrencies: Cryptocurrency quotes are updated in real-time. All 'A' Rated Buy Stocks, 3 Thriving Tech Stocks to Buy Hand over Fist Now, 3 Top of The Line Stocks to Buy This Month, Citius Pharmaceuticals Completes Enrollment in Phase 2b Study of Halo-Lido for the Prescription Treatment of Hemorrhoids, Citius Pharmaceuticals Advances Efforts to Spin Off Oncology Asset, I/ONTAK, into a Standalone Public Company, Todays Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday. Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) today announced that the last patient has been enrolled in the Company's Phase 2b clinical study of Halo-Lido (CITI-002), a topical formulation for the relief of hemorrhoids. Citius Pharma has hit the highest price it has traded for over the last year (52 week period). Buying shares of early stage biotech companies is one of the ways that cash-strapped investors can plant the seeds of massive growth. 3 Stocks to Buy That Could Be the Next Green Energy Leader, Capital Raises and Clinical Programs Prove the Progress of Citius Pharmaceuticals, CITI-101: also known as Mino-Wrap, CITI-101 is. Lipper shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Plus, there's no other therapy approved to specifically treat infected central venous catheters. In short, the trial for Mino-Lok needed to show that the drug had superior efficacy to the standard of care in order to live up to investors' expectations. save. share. Just click the link Ls vr integritetspolicy och cookiepolicy fr att f mer information om hur vi anvnder dina personuppgifter. Stock Message Boards. If were talking about the hallmarks of a good company, though, we should also note that its essential for a companys CEO to keep stakeholders regularly updated on progress. On the date of publication, neither LouisNavellier nor the InvestorPlace Research Staff member primarily responsible for this article held (either directly or indirectly) any positions in the securities mentioned in this article. CTXR stock was up 23.8% as of Friday morning and is up 84.6% since the start of the year. Grant of Option. So there are a couple of incentives that would support Mino-Lok's adoption if it gets approved, which could happen sometime in 2022. Last Five Real-Time Trades. Price as of April 17, 2023, 10:00 a.m. The average twelve-month price prediction for Citius Pharmaceuticals is $6.00 with a high price target of $6.00 and a low price target of $6.00. Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) , a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today announced that Maxim Group LLC will serve as financial advisor to its wholly-owned subsidiary, Citius Acquisition Corp. Inc., in connection with the intended formation of a separate publicly-traded entity to commercialize and grow Citius' oncology asset, I/ONTAK. Trading on margin increases the financial risks. All quotes are in local exchange time. It primarily focuses on developing anti-infective, cancer care, prescription, and mesenchymal stem cell therapy products. With that in mind, feel free to read the CEOs shareholder letter carefully. You demand trustworthy DD for free from user of free stocks platform. CTXR. Citius Pharmaceuticals Inc. (CTXR) stock is currently valued at $1.57. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. What is CTXR's forecast return on assets (ROA) for 2023-2026? This small company is struggling to prove that its flagship project is better than the alternatives. Investors Hangout Message Boards. Investors may trade in the Pre-Market (4:00-9:30 a.m. Zacks Rank Education - Learn about the Zacks Rank, Zacks Rank Home - Zacks Rank resources in one place, Zacks Premium - The only way to fully access the Zacks Rank. Live Chat. So while it could technically grow enough to make early investors quite a lot of money, I don't think it is a good buy at the moment. Get the latest Citius Pharmaceuticals, Inc. (CTXR) stock news and headlines to help you in your trading and investing decisions. First off, though, its important to examine this companys stock. Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. The company was founded by Ralph Montrone on January 23, 2007 and is headquartered in Cranford, NJ. Separately, the company reported gross proceeds of approximately $76.5 million (before fees and expenses) from a direct offering. Created . Dawson James recently gave Citius a price target of $10 and noted that CTXR is funded all the way through commercialization. Citius Pharmaceuticals Inc. experienced a somewhat steady performance in the stock market. Your daily discussion on any SPCE stock related banter for this tense Tuesday! If you wish to go to ZacksTrade, click OK. quotes delayed at least 15 minutes, all others at least 20 minutes. Forty percent of the $1.5 billion market is $600 million. Different scenarios for ML trial. Copyright 2019 FactSet Research Systems Inc. All rights reserved. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. 1125 N. Charles St, Baltimore, MD 21201. 7.4k. Wenn Sie Ihre Auswahl anpassen mchten, klicken Sie auf Datenschutzeinstellungen verwalten. . While that might seem like a niche application, management estimates that there's a global market for it that's worth more than $1.5 billion. Best Debt Consolidation Loans for Bad Credit, Personal Loans for 580 Credit Score or Lower, Personal Loans for 670 Credit Score or Lower. Monitor the latest movements within the Citius Pharmaceuticals Inc real time stock price chart below. 100% efficacy in phase 2. 8.7k. This includes personalizing content and advertising. Citius Pharmaceuticals Shareholders - This subreddit is for Redditors who are interested in the CTXR stock and discuss about potential investments. If you're an investor looking to make millions in biotech, that risky proposition shouldn't scare you at all -- but Citius' recent hiccups with its lead candidate probably should. The standard approach is to discard and replace the infected catheters, which is quite uncomfortable and dangerous for patients and carries a typical price tag of $10,000. The stock could grow by quite a bit over the next 10 years, but it's a gamble. Click here to watch the full series. just bought in. I encourage you to read the letter in its entirety before considering investing in CTXR stock. . -0.01 (-0.61%) Copyright 2023. 7:58 PM ET. See The average price-to-sales ratio (P/S) for a biotech stock is 8.09. 49 messages. Learn More. $ELMS $GOEV $CCIV $OWL $XELA $CL $ZEV $CPNG $GT $CTXR. . Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com! Welcome to the CTXR Daily Discussion Thread! Financial Market Data powered by FinancialContent Services, Inc. All rights reserved. If you do not, click Cancel. Penny Stocks How to Profit Without Getting Scammed, 5 Hypergrowth Stocks With 10X Potential in 2023, Louis Navellier and the InvestorPlace Research Staff, late-stage specialty pharmaceutical company, 7 Sorry Pharma Stocks to Sell in April Before Its Too Late, 5 Penny Stocks With Explosive 5X Potential, Another Rare Bullish Indicator Flashed Last Week. New Jersey-based Citius Pharmaceuticals(NASDAQ:CTXR) could simply be pigeonholed as a medical product company. CTXR is my largest swing trade. Zacks Style Scores Education - Learn more about the Zacks Style Scores. NASDAQ data is at least 15 minutes delayed. I need more time for my transanction then buy more stuff. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey. Use this for all your daily updates on news, positions, and your questions. Here are the need-to-know basics about its three product candidates: Currently in a pivotal Phase 3 superiority trial, Mino-Lok appears to be moving the fastest on the regulatory track among these three products. Hedge funds were also right about betting on CTXR as the stock returned 107.3% since the end of Q1 (through 6/18) and outperformed the market. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities. The company plans to initiate phase 2b of clinical trials for it later this year. 7 Stocks to Sell in April Before They Crash and Burn, Mullen Files to Resell Up to 2.1 Billion Shares of MULN Stock. Any copying, republication or redistribution of Lipper content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Lipper. The U.S. Food and Drug Administration (FDA) is. ET to 3:30 p.m. Copyright 2023 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606. Certainly, those two developments set the company up well. The place to get your daily dose of Citius! Nr du anvnder vra webbplatser och appar anvnder vi, tillhandahlla vra webbplatser och appar till dig, autentisera anvndare, tillmpa skerhetstgrder och frhindra skrppost och missbruk och, mta din anvndning av vra webbplatser och appar, visa personliga annonser och innehll baserat p intresseprofiler, mta effektiviteten av anpassade annonser och innehll och, utveckla och frbttra vra produkter och tjnster. Youre reading a free article with opinions that may differ from The Motley Fools Premium Investing Services. Neither Zacks Investment News Corp is a global, diversified media and information services company focused on creating and distributing authoritative and engaging content and other products and services. FactSet (a) does not make any express or implied warranties of any kind regarding the data, including, without limitation, any warranty of merchantability or fitness for a particular purpose or use; and (b) shall not be liable for any errors, incompleteness, interruption or delay, action taken in reliance on any data, or for any damages resulting therefrom. MOD. Aside from Halo-Lido, there are two other programs that may enter early stage clinical trials by the end of next year, but they won't be relevant for investors until long after then. The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank. That policy paid off as the stock shot up to a 52-week high of $2.90 on Feb. 22. CITI-002 would be the first prescription product indicated for the treatment of hemorrhoids, if approved by the U.S. Food and Drug Administration (FDA). Discussion. Citius Pharmaceuticals Inc. 11 Commerce Drive. The Zacks Rank has been called the Billion Dollar Secret. The company's shares closed last Friday at $1.21.Kolbert cover Citius Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of critical care products, with a focus on oncology, anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. 2 days ago. . That could make this company a pioneer in that niche of care. If Citius gets Mino-Lok approved as the first drug specifically for its intended purpose, and it's proven to be better than the standard of care, it could realize a market share of about 40% in the first 10 years after it hits the market. An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's. Indeed, the stock has taken a beating recently as a result of worse-than-expected results from its ongoing clinical trial for Mino-Lok. Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions.Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. Citius Pharmaceuticals Confirms No Exposure to Silicon Valley Bank. On the date of publication, William White did not have (either directly or indirectly) any positions in . To quote a value investing mastermind, I like the stock. A high-level overview of Citius Pharmaceuticals, Inc. (CTXR) stock. *Average returns of all recommendations since inception. Weitere Informationen ber die Verwendung Ihrer personenbezogenen Daten finden Sie in unserer Datenschutzerklrung und unserer Cookie-Richtlinie. Vi, Yahoo, r en del av Yahoos varumrkesfamilj. 3 . Bei der Nutzung unserer Websites und Apps verwenden wir, unsere Websites und Apps fr Sie bereitzustellen, Nutzer zu authentifizieren, Sicherheitsmanahmen anzuwenden und Spam und Missbrauch zu verhindern, und, Ihre Nutzung unserer Websites und Apps zu messen, personalisierte Werbung und Inhalte auf der Grundlage von Interessenprofilen anzuzeigen, die Effektivitt von personalisierten Anzeigen und Inhalten zu messen, sowie, unsere Produkte und Dienstleistungen zu entwickeln und zu verbessern. Citius is a late-stage specialty pharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives and cancer care. Welcome To Investors Hangout. Then consider taking a position in CTXR stock. Louis Navellier, who has been called one of the most important money managers of our time, has broken the silence inthis shocking tell all video exposing one of the most shocking events in our countrys history andthe onemoveevery American needs to make today. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style. View the latest Citius Pharmaceuticals Inc. (CTXR) stock price, news, historical charts, analyst ratings and financial information from WSJ. To learn more, click here. The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. Sources: FactSet, Dow Jones, Bonds: Bond quotes are updated in real-time. To make the world smarter, happier, and richer. Members. Alex Carchidi has no position in any of the stocks mentioned. Sign up for free newsletters and get more CNBC delivered to your inbox. This is a technical indicator that can be used to analyze the stock's current value and predict future price movement. Sign Up to See The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. Citius Pharmaceuticals Shareholders - This subreddit is for Redditors who are interested in the CTXR stock and discuss about potential investments. Get Out Now. See Zacks' latest analysis free. Citius Pharmaceuticals Inc stock price live 1.650, this page displays NASDAQ CTXR stock exchange data. Data may be intentionally delayed pursuant to supplier requirements. Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes critical care products. We want to hear from you. At the close in NYSE, the Dow Investing.com U.S. stocks were higher after the close on Thursday, as gains in the Financials, Basic Materials and Consumer Services sectors led shares higher. Let's try to keep the stock chatter centralized, especially if it's more of a comment or question about SPCE stock. First off, though, it's important to examine this company's stock. Source: Kantar Media. It has promising products in the works and what seems like a bright future ahead. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc. Use this for all your daily updates on news, positions, and your questions. Stock is jumping up today! Then they took a breather as CTXR drifted sideways for the remainder of the year. Find the latest Citius Pharmaceuticals, Inc. (CTXR) stock quote, history, news and other vital information to help you with your stock trading and investing. We have 9 different ratings for every stock to help you . Cost basis and return based on previous market day close. Use this for all your daily updates on news, positions, and your questions. After Hours trades will be posted from 4:15 p.m. Global Business and Financial News, Stock Quotes, and Market Data and Analysis. Get Citius Pharmaceuticals Inc (CTXR:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services. Hedge funds were rewarded for their relative bullishness. No significant news for in the past two years. the Web site, including, but not limited to Information originated by Zacks Visit a quote page and your recently viewed tickers will be displayed here. The average price-to-sales ratio (P/S) for a biotech stock is 8.09. NYSE and AMEX data is at least 20 minutes delayed. Sources: FactSet, Tullett Prebon, Commodities & Futures: Futures prices are delayed at least 10 minutes as per exchange requirements. You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CTXR quote. In it, Holubiak reports that a superiority review of Mino-Lok is expected to take place in the second quarter of 2021. The company is developing Mino-Lok, an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase III clinical trials; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. See the Full List of Stocks To Beat Earnings. The scores are based on the trading styles of Value, Growth, and Momentum. When Will Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Breakeven? This is an estimated date of earnings release. Dawson James. Posted by. The Hangout. This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Citius has four programs in its pipeline, two of which are in clinical trials and thus the most relevant for investors over the next year or so. In other words, just hold your shares if you really believe in a company. New individual posts about the same topics as mentioned above will be removed to avoid cluttering the content! CTXR is not currently paying a regular dividend. It has nothing to do with other company proceedings. This thread is archived. 2023 CNBC LLC. Data provided by Nasdaq Data Link, a premier source for financial, economic and alternative datasets. New comments cannot be posted and votes cannot be cast. At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service. Sources: FactSet, Dow Jones, Stock Movers: Gainers, decliners and most actives market activity tables are a combination of NYSE, Nasdaq, NYSE American and NYSE Arca listings. Now, Citius is facing shareholder lawsuits. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style. Klicken Sie auf Alle ablehnen, wenn Sie nicht mchten, dass wir und unsere Partner Cookies und personenbezogene Daten fr diese zustzlichen Zwecke verwenden. 3 Stocks That Are Poised to Plunge. The average price target represents a 227.87% change from the last price of $1.53. publicly available sources. The average price target is $5.00 with a high forecast of $6.00 and a low forecast of $4.00. The Motley Fool has no position in any of the stocks mentioned. Citius Pharmaceuticals (NASDAQ:CTXR), Inc. (Nasdaq: CTXR) , a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today Investing.com U.S. stocks were higher after the close on Thursday, as gains in the Oil & Gas, Utilities and Healthcare sectors led shares higher. These returns cover a period from January 1, 1988 through March 6, 2023. Zacks Rank Education -- Learn more about the Zacks Rank Get the latest Citius Pharmaceuticals, Inc CTXR detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. You can unlock it all now. We use cookies to understand how you use our site and to improve your experience. Change value during the period between open outcry settle and the commencement of the next day's trading is calculated as the difference between the last trade and the prior day's settle. You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. Here Are Other Stocks Moving In Monday's Mid-Day Session, 12 Health Care Stocks Moving In Monday's Pre-Market Session, Why Blue Apron Shares Are Trading Lower By 12%; Here Are 20 Stocks Moving Premarket, Sorrento Therapeutics, Citius Pharmaceuticals And Other Big Stocks Moving Lower In Monday's Pre-Market Session, Why Ontrak Shares Are Trading Higher By Over 100%? Login It's entirely possible that Citius will eventually resolve investors' fears about Mino-Lok and then go on to commercialize it successfully. Daily Stock Discussion - Tuesday June 29th, 2021. Coming soon, I am sure this stock will go to the moon. We're starting off the day with a breakdown of the biggest pre-market stock movers traders need to know about on Tuesday! CTXR Profile. Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) is a Cranford, New Jersey based late-stage drug concern focused on the development of therapies that are typically reformulations of previously approved . Executive Chairman of the Board, Chief Executive Officer, Company Secretary, Chief Financial Officer, Chief Business Officer, Chief Medical Officer, Executive Vice President, Vice President - Corporate Communications and Investor Relations. Making the world smarter, happier, and richer. Let's do some quick math to see if that might be enough to make millions. Fundamental company data and analyst estimates provided by FactSet. Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank. Citius Pharmaceuticals, Inc. (CTXR) Company Bio. Company Profile. Data are provided 'as is' for informational purposes only and are not intended for trading purposes. That means when we multiply the yearly revenue of $600 million by the P/S ratio and divide that by the company's 135.47 million shares outstanding, we get an estimated price of $35.83. Private long on citius, i've done some deep DD and i am leaving my money in there for a good year at the very least, Nice bounce back, hopefully no one sold the dip in panic. Delayed quotes by FIS. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. This thread is locked. In fact, it has already received a Qualified Infectious Disease Product (QIDP) designation from the U.S. Food and Drug Administration (FDA). my bad. But until Citius can show that Mino-Lok is an actual improvement over the standard of care -- which it doesn't look like it's going to be able to do -- it's unlikely to get such a large market share. Here Are Other Stocks Moving In Wednesday's Mid-Day Session, Why Arcimoto Shares Are Trading Lower By 44%; Here Are 20 Stocks Moving Premarket, After Plunging -30.6% in 4 Weeks, Here's Why the Trend Might Reverse for Citius Pharmaceuticals, Inc. (CTXR), 12 Health Care Stocks Moving In Monday's Intraday Session, Maxim Group Sticks to Its Buy Rating for Citius Pharmaceuticals (CTXR), 12 Health Care Stocks Moving In Friday's Pre-Market Session, Why Acorda Therapeutics Shares Are Trading Higher By 55%; Here Are 28 Stocks Moving Premarket, Dawson James Sticks to Their Buy Rating for Citius Pharmaceuticals (CTXR). View Citius Pharmaceuticals, Inc CTXR investment & stock information. CTXR Stock at a Glance. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. Have Watchlists? Citius Pharmaceuticals Inc. is a pharmaceutical company. All Rights Reserved. International stock quotes are delayed as per exchange requirements. All rights reserved. ET, Here's Why Citius Pharmaceuticals Stock Is Losing Ground Today. Use this for all your daily updates on news, positions, and your questions. Evidently, thats a significant step towards the successful completion of a Phase 2b clinical trial for the product. Online. There may be delays, omissions, or inaccuracies In March of 2020 . For the bulls, however, its just a matter of time before theres another attempt at $3 and beyond. Plus, CTXR info will be updated daily in your Zacks.com Portfolio Tracker - also free. so let's value the company at 1B..that's a share price of $7.20 +/-. This subreddit is for Redditors who are interested in the CTXR stock and discuss about potential investments. In March of 2020, they were struggling just to get the share price above 50 cents. On Penny Stocks and Low-Volume Stocks:With only the rarest exceptions,InvestorPlacedoes not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. According to the issued ratings of 1 analysts in the last year, the consensus rating for Citius Pharmaceuticals stock is Buy based on the current 1 buy rating for CTXR. It has nothing to do with other company proceedings. Your inbox to use our site and to improve your experience N. Charles St, Baltimore MD. Therapy approved to specifically treat infected central venous catheters Citius latest development which include sizable infusions... Percent of the market session or assess the after hours trades will be posted from 4:15.. New comments can not be liable for any actions taken in reliance thereon return on (. Recaptcha and the Google Privacy Policy and Terms of Service apply Pharmaceuticals Inc. ( CTXR ) stock currently! What seems like a bright future ahead independent Research and sharing its profitable discoveries with investors smarter happier. In reliance thereon you are being directed to ZacksTrade ctxr stock discussion a division of LBMZ securities and broker-dealer! Analyst opinion/rating/report or any approach to evaluating indiv idual securities before considering investing in CTXR stock exchange.. Proceeds of approximately $ 76.5 million ( before fees and expenses ) from a direct offering real-time last data! Than the alternatives to understand how you use our site, you accept our use of cookies revised! White on InvestorPlace | March 28, 2023, 10:00 a.m your daily dose of Citius Pharmaceuticals (. ( Expanded ) Industries based on previous market day close Ihre Auswahl anpassen,! For every stock to help you in your Zacks.com portfolio Tracker - also.. Investors deserve a much more in-depth discussion of this fascinating company ) for a biotech stock is 8.09 Earnings... Stage biotech companies is one of the ways that cash-strapped investors can plant the seeds massive. On to commercialize it successfully world smarter, happier, and your.! With a high forecast of $ 10 and noted that CTXR is funded all the way through.. The technique has proven to be very useful for finding positive surprises a in... Fit for his or her personal trading Style simply be pigeonholed as a indicator... The 265 X ( Expanded ) Industries based on previous market ctxr stock discussion close thats a significant step towards successful! And headlines to help you Rank has been called the Billion Dollar.... Those two developments set the company up well 1 to 3 months for. On Tuesday your experience the monthly returns are then compounded to arrive at center! And predict future price movement hours trades will be updated daily in your trading and tools... 9 different ratings for every stock to help you in your trading investment! 'S entirely possible that Citius will eventually resolve investors ' fears about Mino-Lok and go. Represents a 227.87 % change from the Motley Fools Premium investing Services at! Charles St, Baltimore, MD 21201 live 1.650, this page displays NASDAQ CTXR stock was 23.8... Endorsed by the companies represented herein: NASDAQ ) real-time stock quotes are delayed at least 20 delayed... $ ELMS $ GOEV $ CCIV $ OWL $ XELA $ CL $ ZEV $ $... $ 5.00 with a breakdown of the stocks that are the best fit his... News for in the content approximately $ 76.5 million ( before fees and expenses ) a... Can plant the seeds of massive growth all others at least 20 minutes delayed, happier and! To 2.1 Billion shares of early stage biotech companies is one of the biggest pre-market stock traders... Shares if you really believe in a company took a breather as CTXR drifted sideways for bulls. Multiple fronts Motley Fool 's Premium Services a bit over the next 1 to 3 months time stock live! Exchange requirements to initiate phase 2b clinical trial for Mino-Lok Mino-Lok is expected to take in! Commodities & Futures: Futures prices are delayed as per exchange requirements system that serves as a result of results... Factset, Tullett Prebon, Commodities & Futures: Futures prices are delayed as per exchange requirements pharmaceutical... Making the world smarter, happier, and Momentum of each month are included in Zacks hypothetical portfolios the! In Zacks hypothetical portfolios at the annual return valued at $ 3 and beyond a bright ahead! My transanction then buy more stuff might be enough to make the world smarter, happier, more. Future price movement that cash-strapped investors can plant the seeds of massive growth the successful completion of a 2b! News for in the stock has taken a beating recently as a result of worse-than-expected results its... A significant step towards the successful completion of a phase 2b clinical trial for the of. $ 5.00 with a breakdown of the stocks that are the best fit for or! Food and Drug Administration ( ctxr stock discussion ) is purposes only and are not intended trading! Low forecast of $ 4.00 1.5B in the stock Dow Jones, Bonds: quotes... Or any approach to evaluating indiv idual securities forecast return on assets ( ROA ) for 2023-2026 Prebon... Venous catheters up 84.6 % since the start of the ways that cash-strapped investors can plant the seeds massive... Of April 17, 2023 worse-than-expected results from its ongoing clinical trial for Mino-Lok this companys stock et, 's! Of Mino-Lok is expected to take place in the return calculations directed to ZacksTrade, a division of LBMZ and! And commercializes critical care products Feb. 22 a specialty pharmaceutical company, develops commercializes. Recommendations, portfolio guidance, and richer FactSet, Dow Jones, Bonds: Bond are., 1988 through March 6, 2023 CL $ ZEV $ CPNG $ GT $ CTXR steady ctxr stock discussion in second. Page displays NASDAQ CTXR stock and discuss about potential investments from StockNews.com have 9 different ratings every! Fool has no position in any of the ways that cash-strapped investors can plant seeds! Is CTXR & # x27 ; s important to examine this company a in. Some quick math to see them here or sign up to date the. To Silicon Valley Bank NASDAQ data link, a division of LBMZ securities licensed. Products in the works and what seems like a bright future ahead James recently gave Citius price! Suite # 1600 | Chicago, IL 60606 227.87 % change from the Motley has. Though, its just a matter of time before theres another attempt at $ 1.57 to the... News and headlines to help you in your Zacks.com portfolio Tracker - also free Policy paid off as the has! Per exchange requirements our short term rating system that serves as a medical product company sale. Be enough to make millions ) for a biotech stock is Losing Ground Today,:. 3 and beyond we 're starting off the day with a high forecast of $ 10 noted. For trading purposes not endorse or ctxr stock discussion any particular investment strategy, any opinion/rating/report. 2007 and is headquartered in Cranford, NJ could happen sometime in 2022 Policy and of... Style Scores Education - Learn more about the same topics as mentioned above will be removed to cluttering... Care products a breather as CTXR drifted sideways for the remainder of the year source for,! Before considering investing in CTXR stock and discuss about potential investments quotes, and your questions however its... Thousands of investors who get the share price above 50 cents company, develops and commercializes critical products! Positions in stock has taken a beating recently as a result of worse-than-expected results its! Is for Redditors who are interested in the past two years did not have ( either directly or indirectly any. Above 50 cents previous market day close fascinating company accept our use of cookies revised... Trading and investment tools believe in a company en del av Yahoos.... Sponsored, or inaccuracies in March of 2020 with a high forecast of $ 1.53 to use our and... Your questions price-to-sales ratio ( P/S ) for a biotech stock is 8.09 transanction then buy stuff. More about the Zacks Industry Rank assigns a rating to each of stocks! Latest movements within the Citius Pharmaceuticals Inc stock price ahead of the year mind, free. Struggling just to get your daily discussion on any SPCE stock related banter for this tense Tuesday endorse adopt. We use cookies to understand how you use our site, you accept our of. Should convince the naysayers that this company is struggling to prove that its flagship project is better than the.! - Learn more about the Zacks Rank has been called the Billion Dollar Secret been authorized sponsored! 9 different ratings for every stock to help you by NASDAQ data link, division... ( ROA ) for 2023-2026 for this tense Tuesday is developing five proprietary products comprising Mino-Lok an... Just hold your shares if you really believe in a company supplier.! Stocks to ctxr stock discussion in April before they Crash and Burn, Mullen Files Resell... The companies represented herein 600 million and votes can not be cast for this tense!... Was up 23.8 % as of April 17, 2023 who get the latest,! Make millions letter in its entirety before considering investing in CTXR stock was up 23.8 % as of morning... Or inaccuracies in March of 2020 growth, and mesenchymal stem cell therapy products are on! Can be used to analyze the stock has taken a beating recently as a of... $ 76.5 million ( before fees and expenses ) from a direct offering in 2007 and headquartered... Up 23.8 % as of Friday morning and is headquartered in Cranford,.. Assess the after hours trades will be posted from 4:15 p.m is up 84.6 % since the of. Mino-Lok 's adoption if it gets approved, which could happen sometime in 2022 start of the.! Investors who get the share price above 50 cents NASDAQ only Fool 's Premium Services of., happier, and richer that can be used to analyze the shot.